Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer?

Trends in Biotechnology

Volumn 27, Issue 5, 2009, Pages 259-265

  Buchholz, Christian J ^a   Mühlebach, Michael D ^a   Cichutek, Klaus ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS; CELL POPULATIONS; CELL SURFACE MEMBRANES; CLINICAL APPLICATIONS; CORE PARTICLES; CYTOSKELETON; ENVELOPE GLYCOPROTEINS; ENVELOPE PROTEINS; HAEMATOPOIETIC SYSTEMS; HUMAN CELLS; LENTIVIRAL VECTORS; MEASLES VIRUS; TRANSFER VEHICLES;

CELL CULTURE; CELL PROLIFERATION; GENE TRANSFER; GLYCOPROTEINS; PROTEINS; VECTORS; VIRUSES;

CELL MEMBRANES;

CD150 ANTIGEN; CD20 ANTIGEN; ENVELOPE PROTEIN; LENTIVIRUS VECTOR; MEMBRANE COFACTOR PROTEIN; VIRUS GLYCOPROTEIN;

ARTICLE; CELL NUCLEUS; CELL SURFACE; CYTOSKELETON; GENE TRANSFER; HUMAN; LYMPHOCYTE; MEASLES VIRUS; NONHUMAN; PLANT GROWTH; PRIORITY JOURNAL; PSEUDOTYPING;

GLYCOPROTEINS; LENTIVIRUS; MEASLES VIRUS; RECOMBINANT PROTEINS; TRANSDUCTION, GENETIC; VIRAL PROTEINS;

MEASLES VIRUS;

EID: 64749102457     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2009.02.002     Document Type: Article

References (55)

1. Barquinero J., et al. Retroviral vectors: new applications for an old tool. Gene Ther. 11 Suppl. 1 (2004) S3-S9
2. Cockrell A.S., and Kafri T. Gene delivery by lentivirus vectors. Mol. Biotechnol. 36 (2007) 184-204
3. Kohn D.B. Lentiviral vectors ready for prime-time. Nat. Biotechnol. 25 (2007) 65-66
4. Sadelain M., et al. Stem cell engineering for the treatment of severe hemoglobinopathies. Curr. Mol. Med. 8 (2008) 690-697
5. Brown B.D., et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat. Biotechnol. 25 (2007) 1457-1467
6. Cathomen T., and Joung J.K. Zinc-finger nucleases: the next generation emerges. Mol. Ther. 16 (2008) 1200-1207
7. Fischer A., and Cavazzana-Calvo M. Gene therapy of inherited diseases. Lancet 371 (2008) 2044-2047
8. Santilli G., et al. Gene therapy of inherited immunodeficiencies. Expert Opin. Biol. Ther. 8 (2008) 397-407
9. Verhoeyen E., et al. IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood 101 (2003) 2167-2174
10. Pierson T.C., and Doms R.W. HIV-1 entry and its inhibition. Curr. Top. Microbiol. Immunol. 281 (2003) 1-27
11. Miyake K., et al. Development of targeted gene transfer into human primary T lymphocytes and macrophages using high-titer recombinant HIV vectors. J. Biotechnol. 129 (2007) 532-538
12. Sandrin V., et al. Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses. J. Virol. 78 (2004) 7153-7164
13. Adamson C.S., and Freed E.O. Human immunodeficiency virus type 1 assembly, release, and maturation. Adv. Pharmacol. 55 (2007) 347-387
14. Funke S., et al. Targeted cell entry of lentiviral vectors. Mol. Ther. 16 (2008) 1427-1436
15. Frecha C., et al. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 112 (2008) 4843-4852
16. Merten C.A., et al. Directed evolution of retrovirus envelope protein cytoplasmic tails guided by functional incorporation into lentivirus particles. J. Virol. 79 (2005) 834-840
17. Stitz J., et al. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1. Virology 273 (2000) 16-20
18. Roche S., et al. Structures of vesicular stomatitis virus glycoprotein: membrane fusion revisited. Cell. Mol. Life Sci. 65 (2008) 1716-1728
19. Cronin J., et al. Altering the tropism of lentiviral vectors through pseudotyping. Curr. Gene Ther. 5 (2005) 387-398
20. Colin A., et al. Engineered lentiviral vector targeting astrocytes in vivo. Glia 57 (2008) 667-679
21. Miletic H., et al. Selective transduction of malignant glioma by lentiviral vectors pseudotyped with lymphocytic choriomeningitis virus glycoproteins. Hum. Gene Ther. 15 (2004) 1091-1100
22. Funke S., et al. Pseudotyping lentiviral vectors with the wildtype measles virus glycoproteins improves titer and selectivity. Gene Ther. (2009) 10.1038/gt.2009.11
23. Yang L., et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 26 (2008) 326-334
24. Russell S.J., et al. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res. 21 (1993) 1081-1085
25. Buchholz C.J., et al. Retroviral display and high throughput screening. Comb. Chem. High Throughput Screen. 11 (2008) 99-110
26. Sandrin V., et al. Targeting retroviral and lentiviral vectors. Curr. Top. Microbiol. Immunol. 281 (2003) 137-178
27. Szecsi J., et al. Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions. Mol. Ther. 14 (2006) 735-744
28. Duerner L.J., et al. Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue. Gene Ther. 15 (2008) 1500-1510
29. Springfeld C., et al. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res. 66 (2006) 7694-7700
30. Morizono K., et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat. Med. 11 (2005) 346-352
31. Yang L., et al. Targeting lentiviral vectors to specific cell types in vivo. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 11479-11484
32. Blechacz B., and Russell S.J. Measles virus as an oncolytic vector platform. Curr. Gene Ther. 8 (2008) 162-175
33. Yusuf I., and Fruman D.A. Regulation of quiescence in lymphocytes. Trends Immunol. 24 (2003) 380-386
34. Muhlebach M.D., et al. Stable transduction of primary human monocytes by simian lentiviral vector PBj. Mol. Ther. 12 (2005) 1206-1216
35. Wolfrum N., et al. Impact of viral accessory proteins of SIVsmmPBj on early steps of infection of quiescent cells. Virology 364 (2007) 330-341
36. Goujon C., et al. Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells. J. Virol. 82 (2008) 12335-12345
37. Korin Y.D., and Zack J.A. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J. Virol. 72 (1998) 3161-3168
38. Yoder A., et al. HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell 134 (2008) 782-792
39. Muller N., et al. Measles virus contact with T cells impedes cytoskeletal remodeling associated with spreading, polarization, and CD3 clustering. Traffic 7 (2006) 849-858
40. Verhoeyen E., et al. Novel lentiviral vectors displaying 'early-acting cytokines' selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells. Blood 106 (2005) 3386-3395
41. Cragg M.S., et al. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8 (2005) 140-174
42. Glennie M.J., et al. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44 (2007) 3823-3837
43. Craxton A., et al. Bim regulates BCR-induced entry of B cells into the cell cycle. Eur. J. Immunol. 37 (2007) 2715-2722
44. Walshe C.A., et al. Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. J. Biol. Chem. 283 (2008) 16971-16984
45. Niggli V., and Rossy J. Ezrin/radixin/moesin: versatile controllers of signaling molecules and of the cortical cytoskeleton. Int. J. Biochem. Cell Biol. 40 (2008) 344-349
46. Naghavi M.H., et al. Moesin regulates stable microtubule formation and limits retroviral infection in cultured cells. EMBO J. 26 (2007) 41-52
47. Hashiguchi T., et al. Crystal structure of measles virus hemagglutinin provides insight into effective vaccines. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 19535-19540
48. In: Coffin J.M., et al. (Ed). Retroviruses (1997), Cold Spring Harbor Laboratory Press
49. Colf L.A., et al. Structure of the measles virus hemagglutinin. Nat. Struct. Mol. Biol. 14 (2007) 1227-1228
50. Navaratnarajah C.K., et al. Dynamic interaction of the measles virus hemagglutinin with its receptor signaling lymphocytic activation molecule (SLAM, CD150). J. Biol. Chem. 283 (2008) 11763-11771
51. Yanagi Y., et al. Measles virus: cellular receptors, tropism and pathogenesis. J. Gen. Virol. 87 (2006) 2767-2779
52. Leonard V.H., et al. Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J. Clin. Invest. 118 (2008) 2448-2458
53. Tahara M., et al. Measles virus infects both polarized epithelial and immune cells by using distinctive receptor-binding sites on its hemagglutinin. J. Virol. 82 (2008) 4630-4637
54. Vongpunsawad S., et al. Selectively receptor-blind measles viruses: identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J. Virol. 78 (2004) 302-313
55. Nakamura T., et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol. 23 (2005) 209-214